Safe Cholecystectomy Multi-Society Practice Guideline and State of the Art Consensus Conference on Prevention of Bile Duct Injury During Cholecystectomy

L. Michael Brunt, MD; Daniel J. Deziel, MD; Dana A. Telem, MD, MPH; Steven M. Strasberg, MD; Rajesh Aggarwal, MD; Horacio Asbun, MD; Jaap Bonjer, MD; Marian McDonald, MD; Adnan Alseidi, MD; Mike Ujiki, MD; Taylor S. Riall, MD, PhD; Chet Hammill, MD; Carol-Anne Moulton, MD; Philip H. Pucher, MD; Rowan W. Parks, MD; Mohammed T. Ansari, MD, MMedSc, MPhil; Saxon Connor, MD; Rebecca C. Dirks, MD; Blaire Anderson, MD; Maria S. Altieri, MD; Levan Tsamalaidze, MD; Dimitrios Stefanidis, MD, PhD


Annals of Surgery. 2020;272(1):3-23. 

In This Article

Guideline Scope, Purpose, and Methods

The aims of the consensus meeting were to identify optimal strategies for the prevention of BDI during cholecystectomy and to develop and disseminate evidence-based practice recommendations for safe cholecystectomy. The guideline takes the surgeon-patient perspective. Topics covered include anatomic identification techniques, disease factors, surgical techniques, surgeon education, and intraoperative management of injury. Intended users of the guideline are general surgeons, hepatobiliary surgeons, and surgical trainees. It is anticipated that use of the guideline will help minimize the variability in surgical care for patients undergoing cholecystectomy, reduce the risk of BDI, and improve associated morbidity, cost, and quality of life. This guideline should also directly inform efforts by surgical training programs, hospitals, and professional associations to create and disseminate interventions to enhance patient safety in cholecystectomy and improve patient outcomes.

Detailed in Appendix 1, and summarized in Table 1,[25–34] the overall guideline-development process was guided by SAGES policies and procedures for guideline development to meet recommendations for trustworthy guidelines by the Institute of Medicine (now the National Academy of Medicine) and the Guidelines International Network.[35–38] The guideline development group leads and working group members are listed in Table 2 and the guideline questions are listed in Table 3.